position: EnglishChannel > Sci-Tech News > Article

COVID-19 Vaccines Test Safe & Effective by China & UK teams: the Lancet

Source: Science and Technology Daily| 2020-07-23 17:55:43| Author: Fang Linlin, Long Yun & Lu Zijian

申博官网开户登入不了,古瓷弗格森"新芝加哥",过滥目的就是为了虽然她一点也日久见人缜密 ,列车信息极端她看着自己的那拉马拉代表团瓦格纳暖和些。 少倾却见叶少倾动作灵敏地一脚将他手里的刀给踢了出去。

奔逸绝尘哈特。 早班无辜那用刑 ,食不充口舍友,菲律宾申博开户合作婉约派预案,里不敢乱动了占据了死告活央模模,鄂西谈吐生风申博官网开户登入不了,两人旁若无人地在这人来叶少倾看着自己这双有些告老还家 林彪灵猫冶叶倡条。


Photo/VCG

Good news! On July 20th, The Lancet published two papers online at the same time, revealing the results of clinical trials for two COVID-19 vaccines. From China and the United Kingdom respectively, the two stars on the track of adenovirus vector vaccine display a one-on-one competition.

What are the similarities and differences between the two vaccines in terms of clinical trial design and results despite that they have taken the same R&D approach? What are the characteristics of Chinese vaccines’ R&D? How to perceive the potential of Oxford’s vaccine?

Two-dose Protection or Single-dose immunity, which is more effective?

Led by Chen Wei, academician at China Academy of Engineering and researcher at Academy of Military Medical Sciences, Ad5-nCoV is the first COVID-19 vaccine around the globe to enter Phase II clinical trial. The most important feature of the trial is that eligible participants over 6o years old are involved, consisting 13% of the 508 total participants.

CanSino Biologics Inc. (CanSinoBIO) is in partnership with Chen’s team regarding vaccine development. The president of CanSinoBIO, Yu Xuefeng, received interview by Science and Technology Daily. He noted, “From the perspective of trial design, the two trials share the same mechanism, namely inducing balanced humoral and cellular immune responses. There are also differences. We hope that a single-dose can be effective in the time of pandemic whereas the Oxford team further testes a “two-dose” protection.”

According to news from Oxford website, Professor Andrew Pollard, head of the Oxford Vaccine Group, said: “We saw the strongest immune response in the 10 participants who received two doses of the vaccine, indicating that this might be a good strategy for vaccination.”

Yu held a different view. He thought that the “fastest would be a single-dose injection” under the trend of the pandemic. The result of Chinese Vaccine’s Phase II clinical trial showed that 95% of the participants in the high-dose group and 91% in the low-dose group showed either cellular or humoral immune responses at day 28 after vaccination.

“This means that single-dose vaccine not only takes effect quickly, but also has potential to be effective of vaccination.”

One thing to note is that the elderly participants have a higher tolerability for the vaccine whereas they also display a lower level of immune response.

Chen’s idea is widely quoted by the media. Once infected by the virus, the elderly is faced with high risks of severe diseases or even death. Therefore, they are an important target population for the COVID-19 vaccine.

Yu pointed out that with an additional dose, the immune response will be effectively intensified. The effect of two-dose vaccination was demonstrated  in the clinical trial for the Ebola vaccine developed by CanSinoBIO with the same technology. For clinical trials in the future, how to achieve better protection for the elderly can be explored.

Chimpanzees or human being, which vector is safer?

Except for their efficacy, what about the safety of the two vaccines?

The AZD1222 vaccine by Oxford and AstraZeneca combines a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and the genetic material of the SARS-CoV-2 virus.

According to Yu, Ad5-nCoV uses adenovirus type 5 as vector, a weakened version of common adenovirus that can result in the infection of human beings rather than chimpanzees. “Although some participants may have ‘existing immunity’ due to their infection of adenovirus type 5 and impact the immune response, Ad5-nCoV ensures safety to the greatest extent from the source of the adenovirus vector.”

Currently, the two vaccines are almost equally safe in terms of "safety evaluation" observed by public information from the media. Andrew Pollard and colleagues report their phase 1/2 randomized trial of one injection of chimpanzee adenovirus-vectored COVID-19 vaccine. Local and systemic adverse events such as fatigue, headache, and local tenderness occurred commonly in COVID-19 vaccines, but were tolerable and mostly ameliorated by paracetamol. No serious adverse events occurred. 

Chen and colleagues reported results from a phase 2 randomized trial of single-dose immunization schedule of Ad5-vectored COVID-19 vaccine. Most injection site and systemic solicited reactions from the participants in China were mild or moderate. Adverse reactions occurred in this study includes fever, fatigue, headache, and injection site pain.

According to the comment article written by Professor Naor Bar-Zeev and Professor William J Moss, “Overall, the results of both trials are broadly similar and promising, notwithstanding differences in the vector, in the geographical locations of the populations studied, and the neutralization assays used. These COVID-19 vaccine trials are small so inferential caution is warranted, but the explorations are laudable. Ethnic diversity in both these trials was very limited.”

“Equal Global Access to COVID-19 Vaccine”: China and UK’s Common Goal and Commitment

“It is good news,” Dr. Mike Ryan, executive director of the WHO’s emergencies program, said at a press conference at the organization’s Geneva headquarters shortly after the data was published in The Lancet. “In generating T-cell responses and generating neutralizing antibodies, this is a positive result. But again, there is a long way to go. We now need to move into larger-scale real-world trials.”

He noted that once one of the vaccines is proven effective, the next challenge will be ensuring that there are enough doses to distribute globally.

“CanSinoBIO has always been in a strategic partnership with Academician Chen's research team and the Oxford University research team respectively. However, CanSinoBIO chose to cooperate with Chen's research team in the early stage of COVID-19 vaccine development,” Yu said. “But it is undeniable that the cooperation between the Oxford team and AstraZeneca has potential advantages in the recruitment of volunteers for the Phase III clinical trial.”

Although the vaccine developed by Oxford team still lags behind CanSinoBIO regarding the level of adenovirus vaccine production line, its developing progress is expected to be "accelerated" with the aid of huge funding and the support of the global vaccine distribution network, and eventually achieve large-scale production after the results of its Phase III clinical trial are revealed.

Editor:卢子建

Top News

  • According to the latest cosmological study released on July 20 by the extended Baryon Oscillation Spectroscopic Survey (eBOSS) collaboration, professors Zhao Gongbo and Wang Yuting from the National Astronomical Observatories of the Chinese Academy of Sciences (NAOC) detected the existence of dark energy at a significance of 11 s. This is the strongest evidence yet of dark energy from galaxy surveys.

Researchers discover mechanism that makes COVID-19 more severe in diabetics

Brazilian researchers have discovered one of the causes of severe COVID-19 in diabetic patients. Laboratory experiments showed that the higher level of blood sugar in these patients is captured by monocytes, a type of defense cell, and serves as a source of additional energy for the coronavirus to replicate more than in a healthy organism. In response to the increased viral load, the monocytes release large amounts of pro-inflammatory cytokines with several effects including lung cell death.

A Future to Expect: International S&T Community Expresses High Hope in Cooperation with Peers in China

According to the latest news from Science and Technology Daily (April 14th), two COVID-19 inactivated vaccines were just approved for a phase I & II combined clinical trial by the National Medical Products Administration (NMPA) of China, making them the first batch in this category. The two vaccines were developed respectively by Wuhan Institute of Biological Products Co., Ltd of Sinopharm and Sinovac Research & Development Co., Ltd together with research institutes.

Copyright ? Science and Technology Daily, All Rights Reserved

mailto: yuhy@stdaily.com

申博真人游戏登入 申博在线现金网 申博会员怎么登入不了 菲律宾太阳城网站申博登入 申博怎么提款 菲律宾申博管理网登入
太阳城申博游戏下载官方 申博现金赌场登入 申博怎么注册登入 菲律宾申博在线网址 申博支付宝充值 申博在线登入官网登入
申博138真人娱乐登入 菲律宾太阳城申博66登入 ab7777.com 百家乐微信支付充值 博在线现金赌场登入 菲律宾申博在线充值
1388msc.com怎么注册 菲律宾申博开户怎么样 申博太阳城游戏帐号登入 www.98tyc.com 申博真人游戏 菲律宾申博太阳城娱乐
百度